Close Menu

NEW YORK (GenomeWeb) – Transgenomic today announced that it has signed an agreement to sell roughly $3 million in restricted stock and warrants through a private placement.

According to the company, the placement includes 1.5 million shares of restricted common stock, as well as fully paid prefunded warrants to purchase up to approximately 700,000 shares of its common stock, in each case at a purchase price of $1.42 per share.

During early morning trading on the Nasdaq, shares of Transgenomic were trading down 7 percent at $1.55.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.

The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.

People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.

MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.